A service of StreetInsider.com
Ticker Symbol
Welcome

Most Popular

AAPL 472.07
C 33.60
GOOG 608.00
BAC 7.97
RIMM 16.48

Recently Added

SHMX 0.00
NBTH 12.79
COHO 0.00
PZZI 6.14
AIMH 0.01

Gaining Speed

COHO 0.00
PZZI 6.14
SHMX 0.00
NBTH 12.79
PZZA 39.19
19.15 -0.59 (-3.00%) RDEA

Click Here to Receive Instant E-mail and RSS Alerts


Trade RDEA now with

Stock Details

Last Trade:19.15 Change:-0.59 (-3.00%) Prev Close:19.74 Open: 19.68 Days Range:19.04 – 19.93 52 Week Range: 13.15 - 29.58 Volume:97879 P/E: N/A
EPS:-2.10

Member Comments

No member comments available for RDEA


Not logged in - Log in or Sign up to leave comments





View AllRecent Alerts 02/08/12

Recent Alert on 02/06/12 at 4:03pm
Ardea Biosciences (RDEA) Completes Common Stock Offering, Gross Proceeds $166.2 Million

Ardea Biosciences, Inc. (NASDAQ: RDEA) announced the completion of an underwritten public offering of 9,775,000 shares of its common stock, including 1,275,000 shares sold pursuant to the full exercise of an over-allotment option previously granted... Read More

Recent Alert on 02/01/12 at 8:56am
Ardea Biosciences (RDEA) Lower Following Pricing of 8.5M Common Offering
Recent Alert on 02/01/12 at 8:56am
Ardea Biosciences (RDEA) Lower Following Pricing of 8.5M Common Offering
Recent Alert on 02/01/12 at 8:54am
Ardea Biosciences (RDEA) Prices 8.5M Common Offering at $17/Share
Recent Alert on 01/19/12 at 7:36am
Collins Stewart Starts Ardea Biosciences (RDEA) at Buy; Lesinurad to Fill Hole in Gout Market

View AllRecent Press Releases

Press Release on 02/06/12 at 4:01pm
Ardea Biosciences Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock

View AllRecent SEC Filings

SEC Filing on 02/06/12 at 4:03pm
Form 8-K Ardea Biosciences, Inc./ For: Feb 01
SEC Filing on 02/06/12 at 6:16am
Form SC 13D/A Ardea Biosciences, Inc./ Filed by: BAKER JULIAN

View AllRecent Blog Posts

Blog Posts on 01/08/12 at 2:57am
16 Healthcare Stocks Insiders Want Most
Blog Posts on 12/29/11 at 3:52pm
14 Undervalued Stocks Backed By Insider Buying
Blog Posts on 12/07/11 at 3:44pm
Savient's Krystexxa: How I Get A $209 Million Sales Estimate By 2015
Blog Posts on 12/06/11 at 12:11pm
Biotech-Focused Baker Bros.' Top Q3 Picks
Blog Posts on 12/02/11 at 1:39pm
Savient Pharmaceuticals: The Potential Role Of Krystexxa The Treatment Of Gout